Cite

HARVARD Citation

    Hurabielle, C. et al. (2017). Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft‐versus‐host disease. British journal of dermatology. pp. e206-e208. [Online]. 
  
Back to record